The role of amrinone in treating heart failure during and after coronary artery surgery supported by cardiopulmonary bypass.
Amrinone and dobutamine compare favorably in the treatment of chronic congestive heart failure. There is increasing evidence that amrinone alone or in combination with a catecholamine may be used with considerable success in treating patients who are difficult to wean from cardiopulmonary bypass or who have a low cardiac output syndrome after coronary artery bypass grafting surgery. Amrinone increases intramyocardial cyclic adenosine monophosphate and exerts positive inotropic activity in addition to being a potent vasodilator. It may also improve diastolic function by increasing sarcoplasmic reticulum reuptake of calcium during diastole. It has been administered to patients prior to weaning from cardiopulmonary bypass and has improved hemodynamics and oxygen transport. When compared with dobutamine as primary treatment for depressed myocardial function in patients being weaned from cardiopulmonary bypass after coronary artery bypass grafting surgery, it was more effective in achieving primary treatment objectives. Patients given dobutamine had a higher incidence of myocardial infarction, ventricular fibrillation, supraventricular tachyarrhythmias, sinus tachycardia, and hypertension compared to those given amrinone. It is concluded that amrinone compares favorably with dobutamine and may even be superior when used as primary treatment for treating myocardial depression in patients having coronary artery surgery supported by cardiopulmonary bypass.